Biologically active fragments of glucagon-like insulinotropic peptide

• US 5,574,008 A
• Filed: 08/30/1994
• Issued: 11/12/1996
• Est. Priority Date: 08/30/1994
• Status: Expired due to Fees

• Current Assignee: Eli Lilly and Company
• Original Assignee: Eli Lilly and Company
• Inventors: Johnson, William T., Yakubu-Madas, Fatima E.
• Primary Examiner(s): Allen, Marianne P.
• Application Number:
  US08/297,731
• Time in Patent Office: 805 Days
• Field of Search: 530/303, 530/308, 530/324, 514/3, 514/2, 514/12, 514/13, 514/14, 514/866, 435/69.1, 435/69.4
• US Class Current: 514/6.9
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: C07K 14/605 Glucagons

Abstract

N-terminal truncated forms of glucagon like insulinotropic peptide (GLP-1) and analogs thereof are provided. The claimed polypeptides promote glucose uptake by cells but do not stimulate insulin expression or secretion. The invention also provides methods for treating diabetes and pharmaceutical formulations comprising the claimed polypeptides.

Claims

1. A GLP- 1 fragment of the formula:

space="preserve" listing-type="equation">R.sup.1 -Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-TrP-Leu-Val-X-Gly-Arg-R.sup.2 (SEQ ID NO;

1)

wherein R¹ is selected from the group consisting of;

a) H₂ N-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser (SEQ ID NO;

7); and

,

b) H₂ N-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser (SEQ ID NO;

8);

X is selected from the group consisting of Lys and Arg;

and wherein R² is selected from the group consisting of NH₂, OH, Gly-NH₂, and Gly-OH, with the proviso that when R¹ is b) and R² is Gly-NH₂ or Gly-OH, X must be Arg.

2. The GLP-1 fragment of claim 1 that has the amino acid sequence:

H₂ N-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-NH₂ (SEQ ID NO;

9).

3. A pharmaceutical composition comprising the GLP-1 fragment of claim 2 in combination with a pharmaceutically acceptable carrier, diluent, or excipient.

4. A method of treating diabetes in a mammal comprising administering to a mammal in need of such treatment an effective amount of the GLP-1 fragment of claim 2, or a pharmaceutically acceptable salt thereof.

5. The method of claim 4 wherein the mammal is a human being.

6. A method of treating diabetes in a mammal comprising administering to a mammal in need of such treatment an effective amount of a GLP-1 fragment of claim 1, or a pharmaceutically acceptable salt thereof.

7. The method of claim 6 wherein the mammal is a human being.

8. The GLP-1 fragment of claim 1 that has the amino acid sequence:

H₂ N-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-NH₂ (SEQ ID NO;

13).

9. A pharmaceutical composition comprising the GLP-1 fragment of claim 8 in combination with a pharmaceutically acceptable carrier, diluent, or excipient.

10. A method of treating diabetes in a mammal comprising administering to a mammal in need of such treatment an effective amount of the GLP-1 fragment of claim 8, or a pharmaceutically acceptable salt thereof.

11. The method of claim 10 wherein the mammal is a human being.

12. The GLP-1 fragment of claim 1 that has the amino acid sequence:

H₂ N-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly-OH (SEQ ID NO;

10).

13. A pharmaceutical composition comprising the GLP-1 fragment of claim 12 in combination with a pharmaceutically acceptable carrier, diluent, or excipient.

14. A method of treating diabetes in a mammal comprising administering to a mammal in need of such treatment an effective amount of the GLP-1 fragment of claim 12, or a pharmaceutically acceptable salt thereof.

15. The method of claim 14 wherein the mammal is a human being.

16. The GLP-1 fragment of claim 1 that has the amino acid sequence:

H₂ N-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-NH₂ (SEQ ID NO;

11).

17. A pharmaceutical composition comprising the GLP-1 fragment of claim 16 in combination with a pharmaceutically acceptable carrier, diluent, or excipient.

18. A method of treating diabetes in a mammal comprising administering to a mammal in need of such treatment an effective amount of the GLP-1 fragment of claim 16, or a pharmaceutically acceptable salt thereof.

19. The method of claim 18 wherein the mammal is a human being.

20. A pharmaceutical composition comprising a GLP-1 fragment of claim 1 in combination with a pharmaceutically acceptable carrier, diluent, or excipient.

21. A method of treating diabetes in a mammal comprising administering to a mammal in need of such treatment an effective amount of a GLP-1 fragment having the amino acid sequence:

##STR1##

22. The method of claim 21 wherein the mammal is a human being.